The proliferation of cannabinoid products in the market—including ingestibles, topicals, and pet products—at a time when the FDA has yet to clarify a regulatory pathway forward has resulted in confusion in the marketplace. Coupled with warning letters issued by FDA and FTC involving disease claims, and litigation by the plaintiff bar means CBD is and remains a hot-button issue. NIA has invited speakers from the newly formed CBD Association, FDA and FTC to join an extended panel to shed light on what lies ahead.
From the new data privacy regulations that went into effect in January, to the recent win for FTC's position on placebo-controlled clinical trials for health claims, the legal landscape has changed in the past year. We've invited experts to give us an overview of the changing legal landscape and what we must be aware of going forward.
A recent study showed daily supplementation of a bioavailable form of curcumin improved memory. It is still to be determined precisely how it works. As we live longer, maintaining good health, including brain health, is on the top of the list both on an individual basis and in terms of national healthcare costs. This session with a leading researcher on brain health and cognitive function will offer insights into the early research and potential opportunity.
Never has packaging been more important as manufacturers and brand owners alike see increased demand to reduce waste and carbon footprint. When customers know that the product is made of sustainable materials, they see a particular brand is a socially responsible choice. This improved brand image can improve market share and the bottom line. Packing experts will show us how.
While there are arguments by some industry leaders that the tariffs on Chinese goods have been a long time coming and even necessary to reset trade imbalances, they still impact costs along the supply chain and, ultimately, prices to consumers. Speakers will address the impact within their businesses, solutions that may be available, and what the future could hold.
Key regulations are coming to the forefront in 2020. Some like FSMA, are not new but are still surprising manufacturers undergoing FDA inspections. Others like the recent updates to labeling requirements are catching brand owners unaware and unprepared. Just over half of the facilities inspected by FDA in 2019 received a 483, and the biggest percentage of citations were over basics! A high-level overview of what matters most will provide a checklist for those not yet up to speed.